262 related articles for article (PubMed ID: 10556185)
21. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
22. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
24. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
[TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
26. Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
Lagunju IA; Brown BJ; Sodeinde OO
Niger Postgrad Med J; 2013 Sep; 20(3):181-7. PubMed ID: 24287747
[TBL] [Abstract][Full Text] [Related]
27. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
28. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT
Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294
[TBL] [Abstract][Full Text] [Related]
29. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
[TBL] [Abstract][Full Text] [Related]
30. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
31. Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood.
Meier ER; Byrnes C; Weissman M; Noel P; Luban NL; Miller JL
Pediatr Blood Cancer; 2011 Jan; 56(1):103-9. PubMed ID: 21108444
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
Gulbis B; Haberman D; Dufour D; Christophe C; Vermylen C; Kagambega F; Corazza F; Devalck C; Dresse MF; Hunninck K; Klein A; Le PQ; Loop M; Maes P; Philippet P; Sariban E; Van Geet C; Ferster A
Blood; 2005 Apr; 105(7):2685-90. PubMed ID: 15604217
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.
Aygun B; Mortier NA; Kesler K; Lockhart A; Schultz WH; Cohen AR; Alvarez O; Rogers ZR; Kwiatkowski JL; Miller ST; Sylvestre P; Iyer R; Lane PA; Ware RE;
Br J Haematol; 2015 Apr; 169(2):262-6. PubMed ID: 25612463
[TBL] [Abstract][Full Text] [Related]
34. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
[TBL] [Abstract][Full Text] [Related]
35. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
36. Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program.
Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
Eur J Haematol; 2022 Nov; 109(5):465-473. PubMed ID: 35811388
[TBL] [Abstract][Full Text] [Related]
37. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
[TBL] [Abstract][Full Text] [Related]
38. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
[TBL] [Abstract][Full Text] [Related]
39. Expanding the role of hydroxyurea in children with sickle cell disease.
Rogers ZR; Buchanan GR
J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
[No Abstract] [Full Text] [Related]
40. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
